Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teijin Pharma Signs Gout Drug Marketing Rights Deal With Astellas Taiwan

This article was originally published in PharmAsia News

Executive Summary

Teijin Pharma of Japan May 12 signed a marketing agreement with Astellas Taiwan, a subsidiary of Astellas Pharmaceutical, which grants excusive marketing rights for gout durg Uloric (febuxostat) to Astellas in Taiwan. Positioned as one of Teijin's global products, febuxostat obtained approvals in Europe in April 2008. After obtaining U.S.FDA approval in February, it was marketed jointly with Takeda Pharmaceutical starting in March. In Asia, the drug is under review by Korea FDA. Taiwan has a high gout prevalence compared to other Asian countries. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts